Background: A casein-based formula containing TGF-β has been successfully used in adolescents during acute episodes of Crohn's disease. The role played by this molecule requires confirmation. We have examined the capacity of a TGF-β containing diet to control the intestinal inflammation in HLA-B27 transgenic rats, and compared its effects with a similar diet devoid of TGF-β. Methods: Three groups of rats were studied. HLA-B27/hβ2M transgenic rats were fed with a casein-based rat-adapted diet containing TGF-β or a control casein-based diet without TGF-β. Fischer control animals were fed the latter. Body weight, dietary intake, tissue weights, fecal samples, leukocyte counts, and acute phase response were analyzed. Intestinal inflammation was assessed by histology, myeloperoxidase, and mRNA expression of cytokines. MUC2 protein expression was assessed by immunohistochemistry. Breakdown of muscle protein was examined. Results: The test diet improved diarrhea increasing the fecal dry matter and the colonic inflammation as shown by a lower inflammatory score (2.43 ± 1.13 vs 4.42 ± 0.53, p < .05), lower mucosal thickness (431.25 ± 72.29 vs 508.57 ± 81.32 ?m, p = .08) and decreased IFN7 mRNA expression. MUC2 protein expression was increased in HLA rats fed the TGF-β diet compared with HLA rats fed the control diet, but restitution to normal pattern was not observed. The test diet also decreased leukocytosis and the acute phase response and improved the muscle catabolic response. Conclusion: The TGF-β containing diet has a beneficial effect in an animal model of intestinal inflammation. Our observations support a potential role for dietary TGF-β in the restoration of immune homeostasis.
Get full access to this article
View all access options for this article.
References
1.
1. Strober W, Fuss IJ, Blumberg RS. The immunology of the mucosal models of inflammation. Annu Rev Immun.2002;20:495–549.
2.
2. Strober W, Fuss IJ, Ehrhardt RO, et al. Mucosal immunoregulation and inflammatory bowel disease: new insights from murine models of inflammation. Scand J Immunol.1998;48:453–458.
3.
3. Pirzer U, Schonhaar A, Fleischer B, et al. Reactivity of infiltrating T lymphocytes with microbial antigens in Crohn's disease. Lancet.1991;16:338:1238–1239.
4.
4. MacDonald TT. Effector and regulatory lymphoid cells and cytokines in mucosal sites. Curr Top Microbiol Immunol.1999;113–135.
5.
5. Pardoux C, Ma X, Gobert S, et al. Dowregulation of interleukin 12 (IL-12) responsiveness in human T cells by transforming growth factor-beta: relationship with IL-12 signaling. Blood.1999;93:1448–1455.
6.
6. Duchman R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol.1995;102:448–455.
7.
7. Fuss IJ, Boirivant M, Lacy B, Strober W. The interrelated roles of TGF-β and IL-10 in the regulation of experimental colitis. J. Immunol.2002;168:900–908.
8.
8. Rugtveit J, Brandtzaeg P, Hasktensen TS, et al. Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral monocytes. Gut.1994;35:669–674.
9.
9. Smith PD, Smythies LE, Mosteller-Barnum M, et al. Intestinal macrophages lack CD14 and CD89 and consequently are down-regulated for LPS- and IgA-mediated activities. J. Immunol.2001;167:2651–2656.
10.
10. Zareie M, Singh PK, Irvine EJ, et al. Monocyte/macrophage activation by normal bacteria and bacterial products. Implications for altered epithelial function in Crohn's disease. Am J Pathol.2001;158:1101–1109.
11.
11. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumor necrosis factor a, IL-6 and IL-lβ by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol.1993;94:174–181.
12.
12. Suzuki M, Hisamatsu T, Podolsky DK. Gamma interferon augments the intracellular pathway for lipopolysaccharide (LPS) recognition in human intestinal epithelial cells through coordinated up-regulation of LPS uptake and expression of the intracellular toll-like receptor 4-MD2 complex. Infect Immun.2003;71:3503–3511.
13.
13. Madara JL. Pathobiology of neutrophil interactions with intestinal epithelia. Aliment Pharmacol Ther.1997; ll(Suppl):57–62.
14.
14. vonLampe B, Barthel B, Coupland SE, et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut.2000;47:63–73.
15.
15. Brewerton DA, Hart FD, Caffrey M, et al. Ankylosing spondylitis and HL-A 27. Lancet.1973;1:904–907.
16.
16. Taurog JD, Lowen L, Forman J, Hammer RE. HLA-B27 in inbred and non-inbred transgenic mice. Cell surface expression and recognition as an alloantigen in the absence of human β-2 microglobulin. J Immunol.1988;141:4020–4023.
17.
17. Hammer RE, Maika SD, Richardson JA, et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β2m: an animal model of HLA-B27-associated human disorders. Cell.1990;63:1099–1102.
18.
18. El Yousif M, Breuillé D, Papet I, et al. Increased tissue protein synthesis during spontaneous inflammatory bowel disease in HLA-B27 rats. Clin Sci.2003;105:437–446.
19.
19. Faure M, Moennoz D, Mettraux C, et al. The chronic colitis developed by HLA-B27 transgenic rats is associated with altered in vivo mucin synthesis. Dig Dis Sci.2004;49:339–346.
20.
20. Fisher RL. Wasting in chronic gastrointestinal diseases. JNutr.1999;129(suppl):252S–255S.
21.
21. Mercier S, Breuillé D, Mosoni L, et al. Chronic inflammation alters protein metabolism in several organs of adult rats. JNutr.2002;132:1921–1928.
22.
22. Fuss IJ, Boirivant M, Lacy B, Strober W. The interrelated roles of TGF-β and IL-10 in the regulation of experimental colitis. J Immunol.2002;168:900–908.
23.
23. Obermeier F, Dunger N, Demi L, et al. CpG motifs of bacterial DNW exacerbate colitis of dextran sulfate sodium-treated mice. Eur J Immunol.2002;32:2084–2092.
24.
24. Rivera DL, Olister SM, Liu X, et al. Interleukin-10 attenuates experimental fetal growth restriction and demise. FASEB.1998;12:189–197.
25.
25. Voisin L, Breuillé D, Combaret L, et al. Muscle wasting in a rat model of long-lasting sepsis results from the activation of lysosomal, Ca2+-activated and ubiquitin-proteosome pathways. J Clin Invest.1996;97:1610–1617.
26.
26. Walkes TP, Udenfried S. A fluorometric method for the estimation of tyrosine in plasma and tissues. J Lab Clin Invest.1957;50:733–736.
27.
27. Sartor RB. Colitis in HLA-B27/beta 2 microglobulin transgenic rats. Int Rev Immunol.2000;19:39–50.
28.
28. Duffner C, Goldberger C, Falkenbach A, et al. Prevalence, clinical relevance and characterization of circulating CD4 + CD28- T cells in ankylosing spondylitis. Arthritis Res Ther.2003;5:R292–R300.
29.
29. Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto-and microbial antigens. Gastroenterology.2002;123:689–699.
30.
30. Powrie F, Carlino J, Leach MW, et al. A critical role of transforming growth factor β but no interleukin-4 in the suppression of T helper type-1 mediated colitis by CD45Rblow CD4+ T cells. J Exp Med.1996;183:2669.
31.
31. Donnet-Hughes A, Schiffrin EJ, Huggett AC. Expression of MHC antigens by intestinal epithelial cells. Effect of transforming growth factor-beta 2 (TGF-beta 2). Clin Exp Immunol.1995;99:240–244.
32.
32. Donnet-Hughes A, Duc N, Serrant P, et al. Bioactive molecules in milk and their role in health and disease: the role of transforming growth factor-beta. Immunol Cell Biol.2000;78:74–79.
33.
33. Beattie RM, Schiffrin EJ, Donnet-Hughes A, et al. Polymeric nutrition as the primary therapy in children with small bowel Crohn's disease. Aliment Pharmacol Ther.1994;8:609–615.
34.
34. Fell JME, Paintin M, Arnaud-Battandier F, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther.2000;14:281–289.
35.
35. Bannerjee K, Camacho Hübner C, Babinska K, et al. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enterai feeding in Crohn's disease. J Ped Gastroenterol Nutr.2004;38:270–275.
36.
36. Kitani A, Fuss IJ, Nakamura K, et al. Treatment of experimental (trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-βl plasmid: TGF-β 1-mediated suppression of T helper cell type response occurs by interleukin (IL)-10 induction abd IL-12 receptor β2 chain down-regulation. J Exp Med.2000;192:41–52.
37.
37. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science.2000;289:1352–1355.
38.
38. Powrie F, Carlino J, Leach MW, et al. A critical role of transforming growth factor β but no interleukin-4 in the suppression of T helper type-1 mediated colitis by CD45Rblow CD4+ T cells. J Exp Med.1996;183:2669.
39.
39. Strober W, Kelsall B, Fuss I, et al. Reciprocal IFN-? and TGF-β responses regulate the occurrence of mucosal inflammation. Immunol Today.1997;18:61–64.
40.
40. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor β. J Exp Med.2001;194:629–637.
41.
41. Jono H, Shuto T, Xu H, et al. Transforming growth factor-β-Smad signaling pathway cooperates with NF-?? to mediate non-typeable Haemophilus influenzae-induced MUC2 mucin transcription. J Biol Chem.2002;277:45547–45557.
42.
42. Beattie RM, Camacho-Hübner C, Wacharasindhu S, et al. Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease. Clin Endocrinol.1998;49:483–489.
